In Brief: 1996 Rx-to-OTC switch approvals
This article was originally published in The Tan Sheet
Executive Summary
1996 Rx-to-OTC switch approvals: Pfizer's OcuHist among the major Rx-to-OTC switches cleared by the agency in 1996. Approved Jan. 31, 1996 and introduced in April, the NDA for the ocular antihistamine and decongestant with pheniramine maleate .3% and naphazoline HCl .025% was filed by Akorn June 8, 1994. With OcuHist, the agency's major approvals in 1996 totaled eight, not seven, as reported in the Jan. 20 issue of "The Tan Sheet" (p. 12). Other OTC approvals in 1996 that built on earlier switches were McNeil's Junior Strength Motrin 100 mg caplets, in June, and Whitehall-Robins' Junior Strength Advil 100 mg tablets, in December...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning